Inflammatory breast carcinoma : pathological or clinical entity?

• Published in: Breast cancer research and treatment Vol. 64; no. 3; pp. 269 - 273
• Main Authors: RUIZ SIMON, Amparo, CLIMENT DURAN, Miguel Angel, LLUCH HERNANDEZ, Ana, LLOMBART CUSSAC, Antonio, MOYA SAHORI, Vicente, FERNANDEZ-MARTOS, Carlos, GUILLEM PORTA, Vicente
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 01-12-2000; Springer Nature B.V
• Subjects: Adult; Aged; Biological and medical sciences; Breast cancer; Breast Neoplasms - pathology; Cancer research; Cancer therapies; Carcinoma, Ductal, Breast - pathology; Carcinoma, Lobular - pathology; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Middle Aged; Prognosis; Retrospective Studies; Tumors; Human; Carcinoma; Estrogen; Inflammation; Tumoral marker; Malignant tumor; Radiotherapy; Mammary gland diseases; Chemotherapy; Surgery; Female; Advanced stage; Combined treatment; Diagnosis; Mammary gland; Hormonal receptor
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1023/a:1026512722789

Inflammatory breast carcinoma (IBC) diagnosis is usually based in the presence of typical clinical symptoms (redness and edema in more than 2/3 of the breast), which are not always associated with pathologic characteristics (subdermal lymphatics involvement). Whether exclusively pathologic findings without clinical symptoms are sufficient for IBC diagnosis remains controversial. A retrospective analysis of 163 clinically diagnosed IBC (CIC) either with dermal lymphatics invasion or not, was compared with another group of 99 patients with dermal lymphatics invasion without clinical symptoms (occult inflammatory carcinoma) (OIC). The following clinical and pathological characteristics have been analyzed and compared: age, menopausal status, clinical axillar node involvement, symptoms duration before diagnosis, grade, estrogen receptors, presence of metastases at diagnosis, local recurrence, metastasic dissemination, disease-free (DFS) and overall survival (OS). Median age was younger in CIC (52.3 vs. 63.8 years; p < 0.001). Symptom duration before diagnosis were significantly shorter in CIC (3.4 vs. 6.8 months: p < 0.0001). Visceral (36.2% vs. 17.2%; p = 0.001) and brain metastases (7.4% vs. 1%; p = 0.02) was significantly more frequent in CIC. Negative estrogen receptors were more frequent in CIC (34.9% vs. 65.1%: p < 0.004). Five-years DFS (25.6 vs. 51.6%; p < 0.0001) and OS (28.6 vs. 40%; p < 0.05) were shorter in CIC. CIC (regardless of subdermal lymphatics involvement) must be clearly differentiated from OIC. Prognosis of CIC patients is poorer, so this two entities should be clearly differentiated when therepeutic results are reported.